Scholar Rock drops Novo manufacturing site from SMA drug application

NDA FilingNegative

AI Analysis

Summary

Scholar Rock removed a Novo-operated Indiana manufacturing site from its spinal muscular atrophy drug application after the FDA cited the site for deficiencies. This represents a regulatory setback for the program.

Outcome Details

Manufacturing site removed from application due to FDA-cited deficiencies

Importance:6/10

Sentiment:

-0.70

manufacturingFDA deficiencyregulatory setbackSMANDA

Read the original article

Published by Endpoints News on August 10, 2026 5:08 PM

Read Original